Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pain × Cannabidiol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2 Anxiety Disorders 2 Sturge-Weber Syndrome 1 Solid Tumor 1 Parasomnias 1 Pain 1 Nausea 1 Marijuana Abuse 1 Glioblastoma 1 Colonic Neoplasms 1 Cognitive Dysfunction 1 Chemotherapy-Induced Peripheral Neuropathy 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Hepatocellular 1 Cancer Pain 1 Breast Carcinoma In Situ 1 Arthralgia 1

Interventions

Analgesia 6 Morphine 5 Pregabalin 3 Oxycodone 3 Fentanyl 3 ziconotide 2 nabiximols 2 Surveys and Questionnaires 2 Saline Solution 2 Radiofrequency Ablation 2 Methadone 2 Lidocaine 2 Ibandronic Acid 2 Duloxetine Hydrochloride 2 Docetaxel 2 trimebutine 3-thiocarbamoylbenzenesulfonate 1 tanezumab 1 tandutinib 1 siltuximab 1 resiniferatoxin 1 incobotulinumtoxinA 1 imisopasem manganese 1 fulranumab 1 erenumab 1 cyclobenzaprine 1 caffeine, sodium benzoate drug combination 1 Therapeutics 1 Tapentadol 1 Sulindac 1 Soybean Proteins 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡